EverettEVokesMD

Oncology • Chicago, IL

Head & Neck Cancer, Hematologic Oncology, Thoracic Cancer

John E. Ultmann Professor of Medicine and Radiation Oncology, University of Chicago Medicine

Join to view full profile

Dr. Vokes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Vokes' full profile

Already have an account?

Office
5841 S Maryland Ave
Chicago, IL 60637
Phone+1 888-824-0200

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1983 - 1986
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1982 - 1983
Advocate Health Care/Advocate Illinois Masonic Medical CenterResidency, Internal Medicine, 1980 - 1982
University of Bonn Faculty of MedicineClass of 1980

Certifications & Licensure

IL State Medical License 1981 - 2026
IN State Medical License 2023 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2009, 2012-2014
Chicago Magazine: Top Doctors Castle Connolly, 2004, 2006, 2008, 2012, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2008, 2013
Elected Member The American Society for Clinical Investigation, 1998
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer Start of enrollment: 1996 Jun 01
Completed
Phase 2
Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery Start of enrollment: 1998 Jul 01
Completed
Phase 3
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer Start of enrollment: 1999 Oct 01
Completed
Phase 1, Phase 2
ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck Start of enrollment: 2001 Mar 01
Completed
Phase 2
Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Start of enrollment: 2001 Jul 01
Completed
Phase 1
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Start of enrollment: 2004 Nov 01
Completed
Phase 3
A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck Start of enrollment: 2004 Jan 01
Completed
Phase 2
Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer Start of enrollment: 2006 Jun 01
Terminated
Phase 1
Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer Start of enrollment: 2006 Jul 01
Completed
Phase 2
Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck Cancer
Completed
Phase 1, Phase 2
The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2009 Apr 01
Terminated
Phase 2
Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC Start of enrollment: 2010 Mar 01
Completed
Not Applicable
Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC Start of enrollment: 2010 Feb 01
Terminated
Phase 1
Cetuximab and Lenalidomide in Head and Neck Start of enrollment: 2010 Feb 01
Completed
Phase 2
Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer Start of enrollment: 2003 Jan 27
Completed
Phase 2
Organ Preservation in the Multispeciality Therapy of Stage II-IV Locally Advanced Head and Neck Cancer Start of enrollment: 2003 Mar 01
Completed
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Start of enrollment: 2014 May 29
Completed
Phase 3
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25
Completed
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
De-Escalation Therapy for Human Papillomavirus Negative Disease Start of enrollment: 2019 Aug 26
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

77 citations
Somatic acquisition and signaling of TGFBR1*6A in cancer
Boris Pasche, Thomas J. Knobloch, Yansong Bian, Junjian Liu, Sharbani Phukan
JAMA. 2005-10-05
2675 citations
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, Joël Guigay, A. Dimitrios Colevas
The New England Journal of Medicine. 2016-10-08
511 citations
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with anal...
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, Joël Guigay, A. Dimitrios Colevas
Oral Oncology. 2018-06-01

Journal Articles

OPTIMA: A Phase II Dose and Volume De-Escalation Trial for Human Papillomavirus-Positive Oropharyngeal Cancer
L Portugal, E A Blair, J M Melotek, M W Lingen, N Agrawal, A Dekker, Z Gooi, D T Ginat, C C Foster, E E Vokes, D J Haraf, Annals of Oncology

Other

Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy
Vokes EE, Brockstein BE
http://www.uptodate.com/contents/locally-advanced-squamous-cell-carcinoma-of-the-head-and-neck-appro
UpToDate, Wolters Kluwer Health - 2013-04-12
Methods to overcome radiation resistance in head and neck cancer
Vokes EE, Brockstein BE, Yoo DS
http://www.uptodate.com/contents/methods-to-overcome-radiation-resistance-in-head-and-neck-cancer
UpToDate, Wolters Kluwer Health - 2012-04-20
Treatment of metastatic and recurrent head and neck cancer
Vokes EE, Brockstein BE
http://www.uptodate.com/contents/treatment-of-metastatic-and-recurrent-head-and-neck-cancer
UpToDate, Wolters Kluwer Health - 2013-03-05

Press Mentions

Radiation Oncology Physician Groups Unite to Ensure Patient Access to Cancer CareJanuary 9th, 2024
New Study Supports Saving More Lung Tissue in Lung Cancer SurgeriesMarch 24th, 2023
Thomas Spiegel Appointed Vice President and Health System Chief Quality Officer at UChicago MedicineNovember 2nd, 2022
Join now to see all

Grant Support

Program 4 (Clinical And Experimental Therapeutics)National Cancer Institute2008–2012
Tas:: 75 0850 ::Tas Recovery ACT - Actnow Clinical Trial 8418 UnderDivision Of Cancer Treatment2009
Early Therapeutics Development With Phase II EmphasisDivision Of Cancer Treatment2009
Early Therapeutics Development With Phase II EmphasisNational Cancer Institute2007
Carcinogenesis And Novel Therapeutics In Oral CancerNational Institute Of Dental &Craniofacial Research1996–2001
Planning And EvaluationNational Cancer Institute1996–2001
Core--Protocol And Data Management OfficeNational Cancer Institute1996–2001
Cooperative StudyNational Cancer Institute1994–2000
Intravenous Administration Of 14C Losoxantrone (DUP941) For Solid TumorsNational Center For Research Resources1997
Core--Biostatistical And Data Management FacilityNational Cancer Institute1992–1995
Clinical InvestigationsNational Cancer Institute1992–1995